Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mirko Marabese
Observed names:
M Marabese,
M. Marabese,
Marabese, Mirko
Institution:
Mario Negri Institute for Pharmacological Research
Observed institutions:
Università Cattolica del Sacro Cuore,
University of Padua,
University of Milan,
Mario Negri Institute for Pharmacological Research,
Agostino Gemelli University Polyclinic,
Nerviano Medical Sciences,
Fondazione IRCCS Istituto Nazionale dei Tumori
show all 7
ORCID:
0000-0001-9379-0301
Observed ORCID:
0000-0001-9379-0301
OpenAlex ID:
A5016191595
Works
102
Awards
1
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
2013
·
Marina Chiara Garassino
, Olga Martelli
, et al.
·
The Lancet Oncology
·
495
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
2011
·
M.C. Garassino
, M. Marabese
, et al.
·
Annals of Oncology
·
199
Oct‐4 Expression in Adult Human Differentiated Cells Challenges Its Role as a Pure Stem Cell Marker
2007
·
Stefano Zangrossi
, Mirko Marabese
, et al.
·
Stem Cells
·
194
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC
2018
·
Massimo Moro
, Elisa Caiola
, et al.
·
Journal of Thoracic Oncology
·
106
PDF
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
2015
·
Mirko Marabese
, Monica Ganzinelli
, et al.
·
Oncotarget
·
100
PDF
Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
2018
·
Eliana Rulli
, Francesca Ghilotti
, et al.
·
British Journal of Cancer
·
93
PDF
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
2014
·
Laura Brunelli
, Elisa Caiola
, et al.
·
Oncotarget
·
89
PDF
P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.
2001
·
F Vikhanskaya
, S Marchini
, et al.
·
PubMed
·
70
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
2015
·
Elisa Caiola
, Daniela Salles
, et al.
·
Oncotarget
·
55
PDF
p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis
2001
·
Faina Vikhanskaya
, Maria R Bani
, et al.
·
Oncogene
·
55
TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
2012
·
Marina Chiara Garassino
, Olga Martelli
, et al.
·
Journal of Clinical Oncology
·
54
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)
2024
·
C. Proto
, M. Ganzinelli
, et al.
·
Annals of Oncology
·
53
PDF
LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors
2019
·
Elisa Caiola
, Alice Iezzi
, et al.
·
Journal of Thoracic Oncology
·
47
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
2015
·
E. Rulli
, M. Marabese
, et al.
·
Annals of Oncology
·
47
p73: A chiaroscuro gene in cancer
2007
·
Mirko Marabese
, Faina Vikhanskaya
, et al.
·
European Journal of Cancer
·
47
ΔNp63 expression is associated with poor survival in ovarian cancer
2007
·
S. Marchini
, M. Marabese
, et al.
·
Annals of Oncology
·
45
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial
2018
·
Claudio Vernieri
, Diego Signorelli
, et al.
·
Clinical Lung Cancer
·
43
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
2018
·
Elisa Caiola
, Francesca Falcetta
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
43
PDF
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer
2007
·
Mirko Marabese
, Sergio Marchini
, et al.
·
European Journal of Cancer
·
40
DNA damage induces transcriptional activation of p73 by removing C-EBP repression on E2F1
2003
·
M. Marabese
, Faina Vikhanskaya
, et al.
·
Nucleic Acids Research
·
40
PDF
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
2018
·
Anais Del Curatolo
, Fabiana Conciatori
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
39
PDF
Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells
2010
·
Maria Antonietta Sabatino
, Mirko Marabese
, et al.
·
Molecular Cancer
·
39
PDF
Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
2016
·
Laura Brunelli
, Elisa Caiola
, et al.
·
Scientific Reports
·
34
PDF
TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
2012
·
Marina Chiara Garassino
, Olga Martelli
, et al.
·
Journal of Clinical Oncology
·
34
Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic Pain in Cancer Patients
2013
·
Marina Chiara Garassino
, Sheila Piva
, et al.
·
PLoS ONE
·
33
Show more works
View as search
Works count:
102
Citation count:
2,546
H-index:
29
I10-index:
42
Year
Topic
Type